HU-210 has an oralLD50 of 5,000 mg/kg in rats and 14,200 mg/kg in rabbits,[12] and anLDLO (lowest lethal dose) of 143 mg/kg in humans.[12] This is more toxic than Δ8-THC; in monkeys and dogs, 9,000 mg/kg of Δ8-THC was nonlethal.[13][14]
HU-210 is not explicitly listed in thelist of scheduled controlled substances in the USA.[17] A brief profile of HU-210 written and published by theDrug Enforcement Administration (DEA) in 2009, but removed in later years, stated that HU-210 is a Schedule I controlled substance under theControlled Substances Act due to being similar toTHC.[18] A version of the document (updated in 2013), now in PDF form, exists on the DEA Office of Diversion Control's website.[1] In that PDF, the DEA reasserts that HU-210 is a Schedule I substance. The DEA currently considers HU-210 a Schedule I controlled substance under the umbrella of ‘tetrahydrocannabinols’ under CSCN 7370.[19]
HU-210 is a Schedule I controlled substance inAlabama.[20]
(4)a. A synthetic controlled substance that is any material, mixture, or preparation that contains any quantity of the following chemical compounds, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation or compound:
...
9. (6aR, 10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol, some trade or other names: HU-210.
(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances or that contains any of their salts, isomers, including optical, positional, or geometric isomers, homologues, nitrogen-heterocyclic analogs, esters, ethers, and salts of isomers, homologues, nitrogen-heterocyclic analogs, esters, or ethers, if the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation or class description:... 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
^ab"HU-210"(PDF).Office of Diversion Control. Drug Enforcement Administration, U.S. Department of Justice. January 2013. Archived fromthe original(PDF) on 2016-12-28.6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol)] [Purported Ingredient of "Spice"
^abMechoulam R, Lander N, Zahalka J (January 1990). "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative".Tetrahedron: Asymmetry.1 (5):315–318.doi:10.1016/S0957-4166(00)86322-3.
^Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Järbe TU, Hiltunen AJ, et al. (September 1988). "Enantiomeric cannabinoids: stereospecificity of psychotropic activity".Experientia.44 (9):762–4.doi:10.1007/BF01959156.PMID3416993.S2CID19589995.
^Little PJ, Compton DR, Mechoulam R, Martin BR (March 1989). "Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs".Pharmacology, Biochemistry, and Behavior.32 (3):661–6.doi:10.1016/0091-3057(89)90014-2.PMID2544901.S2CID140209484.
^Järbe TU, Hiltunen AJ, Mechoulam R (September 1989). "Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons".The Journal of Pharmacology and Experimental Therapeutics.250 (3):1000–5.doi:10.1016/S0022-3565(25)22722-7.PMID2550611.
^Devane WA, Breuer A, Sheskin T, Järbe TU, Eisen MS, Mechoulam R (May 1992). "A novel probe for the cannabinoid receptor".Journal of Medicinal Chemistry.35 (11):2065–9.doi:10.1021/jm00089a018.PMID1317925.
^Howlett AC, Champion TM, Wilken GH, Mechoulam R (February 1990). "Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor".Neuropharmacology.29 (2):161–5.doi:10.1016/0028-3908(90)90056-w.PMID2158635.S2CID28602221.
^Darlington CL (October 2003). "Dexanabinol: a novel cannabinoid with neuroprotective properties".IDrugs.6 (10):976–9.OCLC112453448.PMID14534855.
^ab"HU-210"(PDF).Material Safety Data Sheet. Cayman Chemical.
^"PART 1308 - Section 1308.11 Schedule I".Office of Diversion Control. Drug Enforcement Administration, U.S. Department of Justice.Archived from the original on 27 August 2009. Retrieved3 May 2018.
N
Y (what is this?) (verify)
